Form 4: Metagenomi's Chief Scientific Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Luis Borges, Chief Scientific Officer of Metagenomi, Inc., reports the acquisition of stock options and restricted stock units.
Summary
- On April 1, 2024, Luis Borges, the Chief Scientific Officer of Metagenomi, Inc., acquired 69,316 restricted stock units (RSUs) at a price of $0.00.
- These RSUs vest with 25% vesting on September 5, 2024, and the remainder vesting in 12 equal quarterly installments, contingent upon continued service.
- On the same date, Borges also acquired options to purchase 291,450 shares of common stock at an exercise price of $10.82.
- These options vest with 25% vesting on August 1, 2024, and the remainder vesting in 36 equal monthly installments, also contingent upon continued service.
- Following these transactions, Borges directly owns 69,316 shares of common stock and options to purchase 291,450 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.
Positives
- The grant of RSUs and stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
- The vesting schedules for both the RSUs and stock options incentivize continued service with the company.
Industry Context
This type of equity compensation is standard practice in the biotech industry to attract and retain key personnel.
Comparison to Industry Standards
- Equity grants are a common component of compensation packages for executives in publicly traded biotechnology companies.
- Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs to incentivize their leadership teams.
- The vesting schedules described are fairly standard, aligning with typical industry practices for retaining key employees.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction for both RSUs and stock options acquisition. |
| 08/01/2024 | First vesting date for 25% of the stock options. |
| 09/05/2024 | First vesting date for 25% of the RSUs. |
| 03/31/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.